Certificates of testing of containers and closures are accepted in lieu of testing without establishing the reliability of the supplier's test results through appropriate validation of the test results at appropriate intervals.
Inspection Record
US Specialty Formulations LLC — FDA 483 Findings
Inspectors Mindy M Chou · Lu ChenThe inspectors who signed the published document.Inspector lookup
View the regulator's official source The source document is always the basis for judgement.
Findings
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established and followed.
The responsibilities and procedures applicable to the quality control unit are not fully followed.
Drug products are not stored under appropriate conditions of temperature so that their identity, strength, quality, and purity are not affected.
The accuracy, sensitivity, specificity and reproducibility of test methods have not been established and docu mented.
There is no written testing program designed to assess the stability characteristics of drug products.
About this record
Extracted automatically from the document US FDA published on 2026-02-03. The source is available at the link above.
This is a record of that moment. Inspection findings are usually followed by the company's response and corrective action, but this page does not know how that turned out. Do not read it as the current state; check the regulator's official announcements for the latest status.
Translation and classification are automated and may differ in nuance from the source.
